News from csl behring A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 02, 2016, 08:00 ET
CSL Behring logo.

CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S.

 CSL Behring's U.S. locations in King of Prussia and Kankakee, Il., and its subsidiary, CSL Plasma headquartered in Boca Raton, Fla., raised...

Dec 22, 2015, 09:00 ET
CSL Behring logo.

CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A

 Global biotherapeutics leader CSL Behring announced today that the company has submitted its Marketing Authorization Application (MAA) to the...

Dec 21, 2015, 09:01 ET
CSL Behring logo.

CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients

 Global biotherapeutics leader CSL Behring announced today that the company has submitted its new drug application to Japan's...

Dec 10, 2015, 18:41 ET

CSL Behring rozširuje prevádzky do Ruska

Pobočka v Moskve posilní prísľub spoločnosti CSL Behring poskytovať pacientom so zriedkavými...

Dec 10, 2015, 13:31 ET

CSL Behring étend ses opérations en Russie

L'ouverture à Moscou renforce la promesse de CSL Behring de livrer ses thérapies de classe mondiale aux patients atteints de maladies...

Dec 10, 2015, 10:28 ET

CSL Behring expandiert Geschäftsaktivitäten in Russland

Moskauer Eröffnung bekräftigt das Engagement von CSL Behring, seine erstklassigen Therapien für Patienten mit seltenen und schweren...

Dec 10, 2015, 09:42 ET

CSL Behring ekspanduje do Rosji

Otwarcie biura moskiewskiego wzmacnia obietnice CSL Behring, iż będzie dostarczała światowej klasy środki lecznicze dla...

Dec 10, 2015, 09:22 ET

CSL Behring expanduje do Ruska

Zahájení činnosti v Moskvě je posílením slibu společnosti CSL Behring poskytovat své...

Dec 10, 2015, 03:00 ET

CSL Behring expande sus operaciones a Rusia

La apertura de Moscú refuerza la promesa de CSL Behring para ofrecer terapias de clase mundial para pacientes con enfermedades raras y graves...

Dec 08, 2015, 08:00 ET
CSL Behring logo.

CSL Behring Expands Operations to Russia

 Global biotherapeutics leader CSL Behring announced today its latest geographic expansion to provide more patients with greater access to...

Dec 07, 2015, 11:00 ET

CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition

 Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and...

Dec 02, 2015, 09:00 ET

CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition

 CSL Behring announced today that it will present several abstracts from its recombinant coagulation factor development programs at the...

Sep 08, 2015, 10:00 ET

Centers for Medicare and Medicaid Services Extends New Technology Add-On Payment for CSL Behring's Kcentra® for Third Year

 CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) again extended the new technology add-on payment...

Aug 25, 2015, 09:01 ET
CSL Behring logo

CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors

 CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK),...

Jul 28, 2015, 09:01 ET

Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B

 CSL Behring announced today that Swissmedic has accepted for review a Marketing Authorization Application (MAA) for the company's...

Jul 28, 2015, 09:00 ET

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A

CSL Behring announced today that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application (BLA)...

Jun 29, 2015, 13:30 ET

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

 CSL Behring announced today that Mohammad Alsharabati, MD, University of Alabama at Birmingham, United States, is the recipient of the 2015...

Jun 24, 2015, 17:16 ET
CSL Behring logo.

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

- Data supports prolonged dosing intervals up to 14 days for routine prophylaxis in hemophilia B patients - Majority of adult and pediatric...

Jun 24, 2015, 08:31 ET
CSL Behring logo.

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

Data Presented during Late Breaking Session at the 2015 ISTH Congress showed: - Patients using rVIII-SingleChain prophylactically to prevent...

Jun 17, 2015, 12:15 ET
CSL Behring logo.

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

 The cost of medicines in general and biopharmaceutical therapies used to treat rare diseases in particular has faced increased attention from...